InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (3 ops.)
Insider track record
ExecutiveDisclosed buys
1
Disclosed sells
3
T+90 hit rate
50%
T+90 mean return
+34.1%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the complete record of transactions filed by Thackray Helen M., Directeur R&D. Director active across 2 companies, notably Biocryst Pharmaceuticals INC. In total, 18 reports have been logged. Split: 1 buy · 3 sells. Total volume traded: €359k. Activity tracked since 14 December 2021. The latest transaction was disclosed on 31 March 2025 (Retenue fiscale). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Thackray Helen M.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations18 total
7,525 shares@ US$7.509.1% of flowCommon StockSEC:0001127602-25-011136:0
125,950 shares0Common StockSEC:0001127602-24-029969:0
6,096 shares@ US$7.397.6% of flowCommon StockSEC:0001127602-24-029969:1
7,150 shares@ US$7.539.0% of flowCommon StockSEC:0001127602-24-029566:0
30,000 shares@ US$5.8628.4% of flowCommon StockSEC:0001127602-24-015371:0
Canonical exit: 12 Aug 2024 (T+90)
7,525 shares@ US$5.086.2% of flowCommon StockSEC:0001127602-24-011832:0
3,074 sharesCommon StockSEC:0001104659-24-014717:0
252 shares@ US$29.6524.4% of flowCommon StockSEC:0001415889-24-000372:0
5,580 shares@ US$6.055.4% of flowCommon StockSEC:0001127602-23-030189:0
51,000 shares0Common StockSEC:0001127602-23-029839:0
472 shares@ US$15.8725.7% of flowCommon StockSEC:0001415889-23-013759:0
397 shares@ US$18.8725.0% of flowCommon StockSEC:0001415889-23-010819:0
7,000 shares@ US$8.299.3% of flowCommon StockSEC:0001127602-23-012587:0
1,953 shares@ US$3.8424.9% of flowCommon StockSEC:0001415889-23-006063:0
81,000 shares0Common StockSEC:0001127602-22-028082:0
3,125 shares@ US$10.895.6% of flowCommon StockSEC:0001127602-22-027887:0
7,600 shares@ US$16.200.0067% mcap100.0% of flowCommon StockSEC:0001127602-22-011188:0
44,000 shares0Common StockSEC:0001127602-21-031130:0
18 of 18 declarations
About Thackray Helen M.
Helen M. Thackray is the Chief R&D Officer at BIOCRYST PHARMACEUTICALS INC. In this role, she oversees the company's research and development initiatives, focusing on innovation and product improvement. Helen brings scientific and technical expertise, enabling her to lead complex research projects. Her commitment to innovation is essential for the success of BIOCRYST.
